" class="no-js "lang="en-US"> Quanterix Appoints Brian Blaser to Board of Directors
Thursday, March 28, 2024

Quanterix Announces Appointment of Brian Blaser to Board of Directors

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023.

Mr. Blaser brings over 25 years of senior leadership experience in the in-vitro diagnostics industry, including 15 years at Abbott Laboratories where he was responsible for the company’s global diagnostics organization, including its core laboratory, point of care, rapid diagnostics, and molecular diagnostics businesses. While at Abbott, he was responsible for the launch of the Alinity family of laboratory instruments and oversaw the acquisition of Alere that made Abbott the global leader in point-of-care and rapid diagnostic testing. Most recently, Mr. Blaser served as a Senior Advisor to McKinsey and is currently a Director and Chair of the Audit Committee for Rockley Photonics. Over his career, he has held key leadership positions in operations, finance, and engineering with the Ortho Clinical Diagnostics division of Johnson & Johnson, Eastman Kodak, and General Motors.

“Throughout his career, Brian has defined and implemented transformational strategies to accelerate growth, increase scale, and dramatically improve profitability,” said Masoud Toloue, CEO at Quanterix. “His history of strategic leadership and breadth of operational excellence further strengthens the collective expertise of our board, and we look forward to leveraging his deep knowledge and experience across clinical and diagnostics settings.”

“I have always been passionate about building diverse teams that thrive on a foundation of exceptional performance, teamwork, and accountability, and I am excited to bring this passion to Quanterix’s Board of Directors at a time when the company is poised for continued success,” said Blaser. “Having led teams that have implemented transformative business strategies to accelerate growth and expansion, I look forward to guiding the company’s mission-critical work as it transitions deeper into its diagnostics strategy.”

Mr. Blaser received his Master of Business Administration from the Rochester Institute of Technology and his Bachelor of Science in Mechanical Engineering Technology from the University of Dayton. He currently serves as Chair of the University of Dayton School of Engineering Advisory Council and as Chairman of the Board of Trustees for Cristo-Rey St. Martin College Prep. Mr. Blaser has also served on the Board of Directors for AdvaMed.

“Brian’s proven experience and significant achievements in diagnostics will be invaluable additions to the company as it continues to expand its commercial potential,” said Martin Madaus, Ph.D., Chairman of Quanterix Board of Directors. “On behalf of the entire board, I am delighted that Brian has decided to step into this new role.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more